Nektar's rezpeg shows promising hair regrowth in alopecia, moving toward Phase 3
TL;DR Summary
Nektar Therapeutics reported that extended treatment with its experimental drug rezpeg led to meaningful hair growth in severe alopecia areata after one year, with 27% of participants reaching SALT Score 20 (80%+ scalp coverage). The response is comparable to or better than low-dose Olumiant, though not tested head-to-head, and Nektar plans to begin a Phase 3 trial later this year.
- Extended use of Nektar Therapeutics drug shows promise in alopecia statnews.com
- 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin Yahoo Finance
- This Biotech Stock Soars on Hair Loss Trial Results. It Isn’t a Cure for Baldness. Barron's
- NKTR Stock Surged To Over Four-Year Highs Today – What’s Driving The Rally? Stocktwits
- Phase 2b 52-Week Extension Results Demonstrate Sustained Hair Regrowth with Rezpegaldesleukin Dermatology Times
Reading Insights
Total Reads
0
Unique Readers
22
Time Saved
2 min
vs 3 min read
Condensed
88%
480 → 60 words
Want the full story? Read the original article
Read on statnews.com